Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$196.24 USD

196.24
1,176,662

-0.58 (-0.30%)

Updated Oct 3, 2024 11:22 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (32 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

3 Reasons Why AbbVie (ABBV) Is a Great Growth Stock

by Zacks Equity Research

AbbVie (ABBV) possesses solid growth attributes, which could help it handily outperform the market.

AbbVie Settles Humira Litigation With Boehringer Ingelheim

by Zacks Equity Research

AbbVie (ABBV) resolves its litigation with Boehringer Ingelheim over U.S. patents for its blockbuster rheumatoid arthritis drug, Humira.

Top Ranked Income Stocks to Buy for May 8th

by Zacks Equity Research

Here are three stocks with buy rank and strong income characteristics for investors to consider today, May 8th.

The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo

Top Ranked Income Stocks to Buy for May 6th

by Zacks Equity Research

Here are four stocks with buy rank and strong income characteristics for investors to consider today, May 6th.

Novo Nordisk (NVO) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Novo Nordisk's (NVO) earnings and sales miss estimates in the first quarter of 2019.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod

by Kinjel Shah

Merck (MRK), Pfizer (PFE), Lilly (LLY) announce Q1 results. European Commission grants approval to AbbVie's (ABBV) Skyrizi and Sanofi's (SNY) Zynquista.

The Zacks Analyst Blog Highlights: Facebook, Comcast, AbbVie, Union Pacific and Air Products

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Facebook, Comcast, AbbVie, Union Pacific and Air Products

Mark Vickery headshot

Top Stock Reports for Facebook, Comcast & AbbVie

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Comcast (CMCSA) and AbbVie (ABBV).

Why AbbVie (ABBV) is a Great Dividend Stock Right Now

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

AbbVie (ABBV) Upgraded to Buy: Here's Why

by Zacks Equity Research

AbbVie (ABBV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 Reasons Why Growth Investors Shouldn't Overlook AbbVie (ABBV)

by Zacks Equity Research

AbbVie (ABBV) is well positioned to outperform the market, as it exhibits above-average growth in financials.

AbbVie (ABBV) Beats on Q1 Earnings & Sales, Raises EPS View

by Zacks Equity Research

AbbVie (ABBV) beats first-quarter estimates for both earnings and revenues. Biosimilar competition impacts Humira sales in ex-U.S. markets. Growth in Imbruvica sales offsets Humira decline.

AbbVie (ABBV) Beats Q1 Earnings and Revenues, Shares Up

by Zacks Equity Research

AbbVie's (ABBV) first-quarter 2018 earnings and revenues both beat estimates. The company raised its guidance for adjusted earnings in 2019.

Kinjel Shah headshot

Pfizer (PFE) to Report Q1 Earnings: Will It Beat Estimates?

by Kinjel Shah

While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and weak sales in the EH segment will hurt.

Kinjel Shah headshot

Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?

by Kinjel Shah

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead to an earnings beat for the company in Q1.

Tracey Ryniec headshot

5 Turnaround Earnings Charts You Must See

by Tracey Ryniec

They were once some of the hottest stocks on the Street. Are they returning to greatness?

Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales

by Zacks Equity Research

Biogen (BIIB) beats estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its muscle disease drug, Spinraza in international markets.

Why Earnings Season Could Be Great for AbbVie (ABBV)

by Zacks Equity Research

AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Beat in Store for AbbVie (ABBV) This Earnings Season?

by Zacks Equity Research

Strong growth of Imbruvica and Mavyret are expected to drive AbbVie (ABBV) first-quarter sales. Declining ex-U.S. Humira sales are likely to be an overhang on the top line.

Biogen (BIIB) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

While sales of Biogen's (BIIB) MS franchise are expected to decline in the first quarter of 2019 that of Spinraza are likely to increase.

Sweta Killa headshot

Can Q1 Earnings Lift Healthcare ETFs Higher?

by Sweta Killa

With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.

AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

AbbVie (ABBV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here Are the Key Takeaways From J&J's Q1 Earnings Report

by Zacks Equity Research

Let's have a look at some of the highlights of J&J's (JNJ) first-quarter 2019 results.

J&J (JNJ) Beats on Q1 Earnings, Ups 2019 Sales Growth View

by Zacks Equity Research

J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019 and raises 2019 guidance for operational sales and adjusted operational EPS growth. Shares up in pre-market trading.